Background
The French "Centre National de Référence en Hémobiologie Périnatale" (CNRHP) is dedicated to biological and clinical diagnosis and treatment of fetomaternal red blood cells incompatibilities. This disease is common and may result in hemolytic disease of the fetus and newborn (HDFN), characterised by anemia and hyperbilirubinemia which may lead to fetal hydrops, kernicterus or death. Three antibodies are associated with severe fetal disease: anti-RH1 (D), anti-RH4 (c) and anti-KEL1 (Kell). High concentration of anti-RH3 (E) can too led to HDFN during the third pregnancy trimestrer. Since the discovery of free fetal DNA into peripheral maternal blood, non-invasive prenatal determination of fetal RHD genotype on maternal blood is used in the management of pregnancies of RH:-1 (D negative) women. CNRHP provide non invasive fetal genotyping as a routine service to help the practitioners to improve the accuracy follow-up in pregnant woman anti-RH1, ant-KEL1, anti-RH4 and anti-RH3 allo-immunised.
The aim of this presentation is the review of non-invasive fetal genotypes used in the CNRHP in determing of feto-maternal RH1, KEL1, RH4 or RH3 incompatibility status in order to spare a specific antenatal monitoring. 
Methods

Conclusion
Non invasive fetal genotyping is a powerful tool to diagnose a feto-maternal red blood cells incompatibility and allows to legitimize a costly and heavy specific antenatal monitoring only to pregnant women carrying incompatible fetus.
UCHP=CNRHP concentration unit determined with standard anti-D
